Pancreatic Neuroendocrine Tumors Market Summary

• The  Pancreatic Neuroendocrine Tumors Market Size is anticipated to grow with a significnat CAGR during the study period (2020-2034).
• The key Pancreatic Neuroendocrine Tumors companies actively involved in the Neuroleptic Malignant Syndrome Treatment include - Novartis, TM Isotope Technologies Munich, Merck, Perspective Therapeutics, and others.

Pancreatic Neuroendocrine Tumors Market and Epidemiology Analysis

• In the stage-wise incident cases, metastatic Pancreatic Neuroendocrine Tumorss and regionally advanced Pancreatic Neuroendocrine Tumorss are high in number in comparison to localized or unstaged. 
• Moreover, the well-differentiated cases comprising G1 and G2 are more in comparison to poorly differentiated (G3) tumors.
• The management of Pancreatic Neuroendocrine Tumors offers a spectrum of options, ranging from conservative approaches for asymptomatic lesions to surgical resection for localized disease. Therapeutic options include SUTENT, LUTATHERA, AFINITOR, and others.
• Pancreatic Neuroendocrine Tumors are a rare type of cancer that starts as a growth of cells in the pancreas. Pancreatic Neuroendocrine Tumors start from the hormone-producing cells in the pancreas called islet cells. Multiple endocrine neoplasia type 1 (MEN1) syndrome is a risk factor for Pancreatic Neuroendocrine Tumors.

Request for Unlocking the CAGR of the "Pancreatic Neuroendocrine Tumors Drugs Market"

Key Factors Driving The Pancreatic Neuroendocrine Tumors Market:

• Rising incidence and improved diagnostics: Increased adoption of advanced imaging and biomarker-based screening is leading to earlier and more accurate detection of pNETs, expanding the treatable patient pool.
• Growing focus on targeted and precision therapies: The shift from conventional chemotherapy to targeted agents, immunotherapies, and peptide receptor radionuclide therapy (PRRT) is boosting market expansion and treatment adoption.
• Strong research investment and expanding clinical pipeline: Multiple late-stage trials, academic–industry collaborations, and regulatory incentives for rare cancers are accelerating innovation in pNET therapeutics.
• Expanding awareness and better disease management guidelines: Improved physician education, patient advocacy efforts, and updated treatment protocols are increasing diagnosis and treatment rates worldwide.
• Rising healthcare spending and market access in emerging regions: Increased availability of advanced oncology care and reimbursement support in Asia-Pacific and Latin America is contributing to market growth.

DelveInsight's “Pancreatic Neuroendocrine Tumors Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Pancreatic Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Pancreatic Neuroendocrine Tumors therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Pancreatic Neuroendocrine Tumors Therapeutics Market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM Pancreatic Neuroendocrine Tumors market size from 2020 to 2034. The report also covers current Pancreatic Neuroendocrine Tumors Treatment Market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Pancreatic Neuroendocrine Tumors Disease Understanding

Pancreatic Neuroendocrine Tumors starts in neuroendocrine cells (islet cells), a special kind of cell found in the pancreas. Neuroendocrine cells are also found in other areas of the body, but only cancers that originate from neuroendocrine cells in the pancreas are called pancreatic neuroendocrine tumors. 

Detailed history taking and physical examination are also important for the diagnosis of patients with Pancreatic Neuroendocrine Tumors. However, the majority of Pancreatic Neuroendocrine Tumors are non-functional tumors and asymptomatic upon diagnosis and are incidentally found in imaging studies. Patients with non-functional Pancreatic Neuroendocrine Tumors sometimes present with symptoms or signs of mass effect or metastasis, including jaundice caused by extrahepatic bile duct occlusion, acute pancreatitis, abdominal pain, and palpable abdominal mass. In the case of functional Pancreatic Neuroendocrine Tumors, the specific symptoms and signs are caused by hormones or peptides they release. Tests and procedures used to diagnose pancreatic neuroendocrine tumors include Blood tests, Urine tests, Imaging tests, endoscopic ultrasound, biopsy, angiogram, laparotomy.

The Pancreatic Neuroendocrine Tumors report provides an overview of Pancreatic Neuroendocrine Tumors pathophysiology, diagnostic approaches, and detailed treatment algorithm along with a real-world scenario of a patient’s journey beginning from the first symptom, the time taken for diagnosis to the entire treatment process.

Further details related to country-based variations in diagnosis are provided in the report...

Pancreatic Neuroendocrine Tumors Treatment

Surgery, the only curative treatment for Pancreatic Neuroendocrine Tumors, is generally considered a first-line treatment. The other treatment includes Surgery, Chemotherapy, Hormone therapy, Hepatic arterial occlusion or chemoembolization, Targeted therapy, and Supportive care. 

Pancreatic Neuroendocrine Tumors Epidemiology

The Pancreatic Neuroendocrine Tumors epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The Pancreatic Neuroendocrine Tumors epidemiology is segmented with detailed insights into Total Incident Cases of Pancreatic Neuroendocrine Tumors, Subtype-specific Cases of Pancreatic Neuroendocrine Tumors, Symptom-based Incidence of Pancreatic Neuroendocrine Tumors, Stage-wise Cases of Pancreatic Neuroendocrine Tumors, Grade-wise Cases of Pancreatic Neuroendocrine Tumors, and Gender-specific Cases of Pancreatic Neuroendocrine Tumors.

Key Findings in the Pancreatic Neuroendocrine Tumors Epidmeiology Analysis

• GEP-NETs represent the second most common digestive cancer in terms of prevalence.
• According to findings, small intestine (30.8%), rectum (26.3%), colon (17.6%), pancreas (12.1%), and appendix (5.7%) are the most common primary NET sites in the digestive tract.
• The old age population is more susceptible to suffering from Pancreatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumors Epidemiology Segmentation

• Total Incident Cases of Pancreatic Neuroendocrine Tumors
• Subtype-specific Cases of Pancreatic Neuroendocrine Tumors
• Symptom-based Incidence of Pancreatic Neuroendocrine Tumors
• Stage-wise Cases of Pancreatic Neuroendocrine Tumors
• Grade-wise Cases of Pancreatic Neuroendocrine Tumors
• Gender-specific Cases of Pancreatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumors Recent Developments

• In March 2025, Exelixis, Inc. announced that the FDA approved CABOMETYX® (cabozantinib) for treating 1) adult and pediatric patients aged 12 and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET), and 2) adult and pediatric patients aged 12 and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET (epNET).
• In January 2025, Elicera Therapeutics received FDA Orphan Drug Designation for its drug candidate ELC-100, aimed at treating pancreatic neuroendocrine tumors, highlighting its potential as a promising therapy for this challenging cancer.

Pancreatic Neuroendocrine Tumors Drugs Analysis

The drug chapter segment of the Pancreatic Neuroendocrine Tumors report encloses a detailed analysis of Pancreatic Neuroendocrine Tumors marketed drugs and late-stage (Phase III and Phase II)  Pancreatic Neuroendocrine Tumors pipeline drugs. It also deep dives into the Pancreatic Neuroendocrine Tumors pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations. 

Pancreatic Neuroendocrine Tumors Marketed Drugs

• LUTATHERA: Novartis

Lutathera (lutetium Lu 177 dotatate*) is a lutetium Lu 177-labeled somatostatin analog peptide. Lutathera belongs to a class of treatments called Peptide Receptor Radionuclide Therapy (PRRT). Lutathera is comprised of a targeting molecule that carries a radioactive component. Lutathera has received orphan drug designation from the FDA and the European Medicines Agency (EMA). It was approved in 2018 by the US FDA for the treatment of adult patients with SSTR-positive GEP-NETs, including those in the foregut, midgut, and hindgut. Lutathera is also approved in Europe for unrespectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptors (SSTR)-positive GEP-NETs in adults, and in Japan for SSTR-positive NETs.

Note: Detailed current therapies assessment will be provided in the full report of Pancreatic Neuroendocrine Tumors...

Pancreatic Neuroendocrine Tumors Emerging Drugs

ITM-11: ITM Isotope Technologies Munich

ITM-11 (177Lu-edotreotide), being developed by ITM Isotope Technologies Munich, is an innovative Targeted Radionuclide Therapy agent consisting of two components: firstly, Edotreotide (DOTATOC), an octreotide-derived somatostatin analog, and secondly, EndolucinBeta (no-carrier-added (n.c.a.) lutetium-177 chloride) a synthetic, low-energy beta-emitting therapeutic radioisotope. It is currently being investigated in two Phase III clinical trials, COMPETE (NCT03049189) and COMPOSE (NCT04919226). While COMPETE is evaluating ITM-11 for the treatment of patients with grade 1 and grade 2 GEP-NETs, the radiopharmaceutical candidate is also being investigated in COMPOSE, for patients with well-differentiated high grade 2 and grade 3 GEP-NETs. ITM-11 received an orphan designation as a treatment for GEP-NETs based on the data from a Phase II clinical study, which demonstrated a significant benefit (substantially improved progression-free survival, PFS).

WELIREG (MK-6482): Merck

Belzutifan (MK-6482) is a novel, potent and selective inhibitor of HIF-2α. Proteins known as hypoxia-inducible factors, including HIF-2α, can accumulate in patients when VHL, a tumor-suppressor protein, is inactivated. If not properly regulated, the accumulation of HIF-2α can stimulate several oncogenes associated with cellular proliferation, angiogenesis, and tumor growth, leading to the growth of both benign and malignant tumors. Currently, it is in Phase II of its clinical development for the treatment of Pancreatic Neuroendocrine Tumors.

Note: Detailed emerging therapies assessment will be provided in the final report....

Pancreatic Neuroendocrine Tumors Market Outlook

Key players, such as ITM Isotope Technologies Munich, Merck, and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of Pancreatic Neuroendocrine Tumors.

Pancreatic Neuroendocrine Tumors Drugs Uptake

This section focuses on the uptake rate of potential Pancreatic Neuroendocrine Tumors drugs expected to be launched in the Pancreatic Neuroendocrine Tumors drugs market during 2024–2034, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key Pancreatic Neuroendocrine Tumors Companies evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake. 

Further detailed analysis of emerging therapies drug uptake in the report…

Pancreatic Neuroendocrine Tumor Pipeline Development Activities

The Pancreatic Neuroendocrine Tumors pipeline report provides insights into different Pancreatic Neuroendocrine Tumor clinical trials within Phase III and Phase II stages. It also analyzes key Pancreatic Neuroendocrine Tumors Companies involved in developing targeted therapeutics. 

 Pancreatic Neuroendocrine Tumors Pipeline Development Activities

The Pancreatic Neuroendocrine Tumors clinical trials analysis report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Pancreatic Neuroendocrine Tumors emerging therapies. 

KOL Views on the  Pancreatic Neuroendocrine Tumors Report

To keep up with the real-world scenario in current and emerging Pancreatic Neuroendocrine Tumors drugs market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging treatment patterns of Pancreatic Neuroendocrine Tumors. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the Pancreatic Neuroendocrine Tumors drugs market and the unmet needs.

Pancreatic Neuroendocrine Tumors Qualitative Analysis

We perform Qualitative and Pancreatic Neuroendocrine Tumors Drugs Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. 

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival. 

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided. 

Pancreatic Neuroendocrine Tumors Drugs Market Access and Reimbursement

In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), third-party organizations that provide services, and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Pancreatic Neuroendocrine Tumors Therapeutics Market Report

• The Pancreatic Neuroendocrine Tumors therapeutics market report covers a segment of key events, an executive summary, descriptive overview of Pancreatic Neuroendocrine Tumors, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country specific treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current Pancreatic Neuroendocrine Tumors treatment market landscape.
• A detailed review of the Pancreatic Neuroendocrine Tumors therapeutics market, historical and forecasted Pancreatic Neuroendocrine Tumors market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Pancreatic Neuroendocrine Tumors therapeutics market report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Pancreatic Neuroendocrine Tumors treatment market.

Pancreatic Neuroendocrine Tumors Therapeutics Market Report Insights

• Patient-based Pancreatic Neuroendocrine Tumors Market Forecasting
• Therapeutic Approaches
• Pancreatic Neuroendocrine Tumors Pipeline Analysis
• Pancreatic Neuroendocrine Tumors Market Size and Trends
• Existing and future Pancreatic Neuroendocrine Tumors Therapeutics Market Opportunity 

Pancreatic Neuroendocrine Tumors Therapeutics Market Report Key Strengths

• 11 Years Forecast
• 7MM Coverage 
• Pancreatic Neuroendocrine Tumors Epidemiology Segmentation
• Inclusion of Country specific treatment guidelines
• KOL’s feedback on approved and emerging therapies 
• Key Cross Competition 
• Conjoint analysis
• Pancreatic Neuroendocrine Tumors Drugs Uptake
• Key Pancreatic Neuroendocrine Tumors Market Forecast Assumptions

Pancreatic Neuroendocrine Tumors Treatment Market Report Assessment

• Current Pancreatic Neuroendocrine Tumors Treatment Market Practices
• Pancreatic Neuroendocrine Tumors Unmet Needs
• Pancreatic Neuroendocrine Tumors Pipeline Product Profiles
• Pancreatic Neuroendocrine Tumors Therapeutics Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• Pancreatic Neuroendocrine Tumors Market Drivers
• Pancreatic Neuroendocrine Tumors Market Barriers 

FAQs

• What is the growth rate of the 7MM Pancreatic Neuroendocrine Tumors treatment market?
• What was the Pancreatic Neuroendocrine Tumors market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors/key catalysts for this growth?
• Is there any unexplored patient setting that can open the window for growth in the future?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends? Although multiple expert guidelines recommend testing for targetable mutations before therapy initiation, why do barriers to testing remain high?
• What are the current and emerging options for the treatment of Pancreatic Neuroendocrine Tumors? 
• How many companies are developing therapies for the treatment of Pancreatic Neuroendocrine Tumors?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies? 
• Patient/physician acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? 

Reasons to buy Pancreatic Neuroendocrine Tumors Market Forecast Report

• The Pancreatic Neuroendocrine Tumors treatment market report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Pancreatic Neuroendocrine Tumors therapeutics Market.
• Insights on patient burden/disease Pancreatic Neuroendocrine Tumors prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing Pancreatic Neuroendocrine Tumors therapeutics market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming Pancreatic Neuroendocrine Tumors companies in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Access Exclusive Data Now! Click here to Read More about the Related Articles:-

• Neuroendocrine tumors (NETs): The complex group of tumors
• Global Neuroendocrine Tumor Market Outlook
• Latest DelveInsight Blogs